# A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

> **NCT07475026** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 198 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT07475026
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2030-01-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07475026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07475026, "A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07475026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*